Mesa Laboratories, Inc (NASDAQ:MLAB) Signals Near-Term Upside As Momentum Recovers

Mesa Laboratories shows recovering technical momentum and improving profitability metrics that point to a constructive near-term setup. WMDST’s valuation identifies the shares as under-valued, reinforcing a bias toward upside into the coming weeks.

Recent News

On March 9, 2026 the company announced a planned leadership transition: Gary Owens will step down as President and CEO effective on or about April 12–13, 2026, with a named successor to assume the role. On March 10, 2026 a company director disclosed an open‑market purchase of 3,500 shares at $72.23 per share via a Form 4 filing.

Technical Analysis

Directional indicators (ADX / DI+ / DI-): ADX sits at 22.58, indicating an emerging trend strength. DI+ shows an increasing trend while DI- trends downward; both read together signal a bullish directional bias that supports the view of near-term upside and aligns with the valuation that labels the stock under-valued.

MACD: MACD equals 0.56 with an increasing trend and a signal line at -0.73; MACD currently sits above its signal line, which constitutes a bullish momentum cross and supports price continuation over the coming weeks.

MRO (Momentum/Regression Oscillator): MRO registers -19.97 and is increasing. The negative reading indicates price sits below WMDST’s intrinsic target, while the rising MRO suggests upward pressure toward that target—consistent with price appreciation potential rather than immediate exhaustion.

RSI and short EMA behavior: RSI at 53.98 shows a recent dip-and-reversal, a bullish pattern. The 12‑day EMA shows a dip-and-reversal while the 20‑day and 50‑day averages lie below the current close, so short-term momentum has flipped positive and the price sits above key moving averages—supporting a constructive near-term technical bias.

Price vs. bands and volatility: The close at $94.26 sits near the upper Bollinger band (upper 2x ≈ $94.29), indicating short-term strength and narrower room before higher-band resistance; 42‑day and 52‑week volatility measures both register ~4%, suggesting moderate realized volatility for tactical positions.

 


Fundamental Analysis

Revenue and margins: Total revenue equals $65,126,000. YoY revenue change shows -16.54%, while the trailing revenue growth reads 7.23%; QoQ revenue change shows 260.40% per the supplied QoQ figure. Gross margin stands at 64.18%, slightly above the industry peer mean of 62.78% and close to the industry peer median of 64.54%, indicating above-average product-level profitability.

Operating profitability: EBIT totals $7,632,000 and EBIT margin equals 11.72%, below the industry peer mean of 20.75% and the peer median of 20.88%. QoQ EBIT margin improved sharply (46.43% QoQ) and improved 10.78% YoY, showing recent operational leverage despite a margin level below peer averages.

Earnings and cash flow: Reported EPS equals $1.76 versus an estimate of $1.47, a beat of $0.29 representing a 19.73% surprise. Operating cash flow reached $18,754,000 and free cash flow totals $18,022,000, producing a free cash flow yield of 4.07%, which sits above the industry peer mean of 0.90%—a favorable signal for cash generation relative to peers. Free cash conversion and cash-to-earnings ratios both indicate strong cash conversion versus net income.

Balance sheet and leverage: Cash and short-term investments equal $28,975,000 while total debt equals $180,979,000 and net debt rests at $137,152,000. Debt-to-assets equals 41.62%, above the industry peer mean of 28.17%, and debt-to-EBITDA measures about 13.56x, indicating meaningful leverage that contrasts with strong cash generation.

Valuation context: Market multiples show a PE of 45.51 and a price-to-book of 2.37, both below the industry peer mean multiples presented. Enterprise multiples also sit below the peer mean. Given above-peer free cash flow yield, improving QoQ profitability and the balance of cash against leverage, WMDST values the stock as under-valued.

Note: earnings results and the company investor presentation provide the reported EPS and revenue context.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-12-31
REPORT DATE: 2026-02-03
NEXT REPORT DATE: 2026-05-05
CASH FLOW  Begin Period Cash Flow 20.4 M
 Operating Cash Flow 18.8 M
 Capital Expenditures -732.00 K
 Change In Working Capital 4.5 M
 Dividends Paid -884.00 K
 Cash Flow Delta 8.6 M
 End Period Cash Flow 29.0 M
 
INCOME STATEMENT REVENUE
 Total Revenue 65.1 M
 Forward Revenue 33.4 M
COSTS
 Cost Of Revenue 23.3 M
 Depreciation 1.3 M
 Depreciation and Amortization 5.7 M
 Research and Development 5.0 M
 Total Operating Expenses 57.2 M
PROFITABILITY
 Gross Profit 41.8 M
 EBITDA 13.3 M
 EBIT 7.6 M
 Operating Income 8.0 M
 Interest Income
 Interest Expense 3.0 M
 Net Interest Income -3.04 M
 Income Before Tax 4.6 M
 Tax Provision 966.0 K
 Tax Rate 21.0 %
 Net Income 3.6 M
 Net Income From Continuing Operations 3.6 M
EARNINGS
 EPS Estimate 1.47
 EPS Actual 1.76
 EPS Difference 0.29
 EPS Surprise 19.728 %
 Forward EPS 1.35
 
BALANCE SHEET ASSETS
 Total Assets 434.8 M
 Intangible Assets 278.9 M
 Net Tangible Assets -92.26 M
 Total Current Assets 105.6 M
 Cash and Short-Term Investments 29.0 M
 Cash 29.0 M
 Net Receivables 40.2 M
 Inventory 26.6 M
 Long-Term Investments 17.2 M
LIABILITIES
 Accounts Payable 5.3 M
 Short-Term Debt 5.2 M
 Total Current Liabilities 54.4 M
 Net Debt 137.2 M
 Total Debt 181.0 M
 Total Liabilities 248.2 M
EQUITY
 Total Equity 186.7 M
 Retained Earnings -180.73 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 33.79
 Shares Outstanding 5.525 M
 Revenue Per-Share 11.79
VALUATION
 Market Capitalization 442.5 M
 Enterprise Value 594.5 M
 Enterprise Multiple 44.543
Enterprise Multiple QoQ -17.325 %
Enterprise Multiple YoY -65.041 %
Enterprise Multiple IPRWA high: 158.913
median: 85.622
mean: 82.996
MLAB: 44.543
low: -144.328
 EV/R 9.129
CAPITAL STRUCTURE
 Asset To Equity 2.329
 Asset To Liability 1.752
 Debt To Capital 0.492
 Debt To Assets 0.416
Debt To Assets QoQ -5.946 %
Debt To Assets YoY 80.294 %
Debt To Assets IPRWA high: 0.828
MLAB: 0.416
mean: 0.282
median: 0.262
low: 0.002
 Debt To Equity 0.969
Debt To Equity QoQ -9.15 %
Debt To Equity YoY 49.104 %
Debt To Equity IPRWA high: 2.909
MLAB: 0.969
mean: 0.54
median: 0.472
low: -1.334
PRICE-BASED VALUATION
 Price To Book (P/B) 2.37
Price To Book QoQ 3.932 %
Price To Book YoY -48.189 %
Price To Book IPRWA high: 15.074
mean: 5.979
median: 5.854
MLAB: 2.37
low: 0.24
 Price To Earnings (P/E) 45.508
Price To Earnings QoQ 29.79 %
Price To Earnings YoY -109.054 %
Price To Earnings IPRWA high: 269.298
mean: 119.739
median: 101.834
MLAB: 45.508
low: -315.07
 PE/G Ratio 0.156
 Price To Sales (P/S) 6.795
Price To Sales QoQ 1.394 %
Price To Sales YoY -39.869 %
Price To Sales IPRWA high: 52.884
median: 23.476
mean: 20.203
MLAB: 6.795
low: -13.339
FORWARD MULTIPLES
Forward P/E 57.092
Forward PE/G 0.196
Forward P/S 13.252
EFFICIENCY OPERATIONAL
 Operating Leverage 7.889
ASSET & SALES
 Asset Turnover Ratio 0.151
Asset Turnover Ratio QoQ 7.344 %
Asset Turnover Ratio YoY 6.758 %
Asset Turnover Ratio IPRWA high: 0.512
MLAB: 0.151
median: 0.133
mean: 0.127
low: -0.209
 Receivables Turnover 1.622
Receivables Turnover Ratio QoQ 5.671 %
Receivables Turnover Ratio YoY 1.774 %
Receivables Turnover Ratio IPRWA high: 2.907
mean: 1.881
median: 1.867
MLAB: 1.622
low: 0.47
 Inventory Turnover 0.859
Inventory Turnover Ratio QoQ 2.52 %
Inventory Turnover Ratio YoY 7.69 %
Inventory Turnover Ratio IPRWA high: 2.05
MLAB: 0.859
mean: 0.67
median: 0.548
low: 0.16
 Days Sales Outstanding (DSO) 56.273
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 141.954
Cash Conversion Cycle Days QoQ -4.892 %
Cash Conversion Cycle Days YoY -8.238 %
Cash Conversion Cycle Days IPRWA high: 453.393
mean: 171.699
median: 165.533
MLAB: 141.954
low: -118.454
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 1.271
 CapEx To Revenue -0.011
 CapEx To Depreciation -0.576
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 347.7 M
 Net Invested Capital 352.8 M
 Invested Capital 352.8 M
 Net Tangible Assets -92.26 M
 Net Working Capital 51.2 M
LIQUIDITY
 Cash Ratio 0.533
 Current Ratio 1.942
Current Ratio QoQ -3.743 %
Current Ratio YoY 173.09 %
Current Ratio IPRWA high: 20.133
mean: 2.709
MLAB: 1.942
median: 1.893
low: 0.168
 Quick Ratio 1.454
Quick Ratio QoQ 0.734 %
Quick Ratio YoY 173.923 %
Quick Ratio IPRWA high: 12.347
mean: 2.035
median: 1.469
MLAB: 1.454
low: 0.366
COVERAGE & LEVERAGE
 Debt To EBITDA 13.56
 Cost Of Debt 1.291 %
 Interest Coverage Ratio 2.514
Interest Coverage Ratio QoQ 48.006 %
Interest Coverage Ratio YoY 1043.066 %
Interest Coverage Ratio IPRWA high: 60.521
median: 25.964
mean: 20.932
MLAB: 2.514
low: -107.569
 Operating Cash Flow Ratio 0.194
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 20.161
DIVIDENDS
 Dividend Coverage Ratio 4.106
 Dividend Payout Ratio 0.244
 Dividend Rate 0.16
 Dividend Yield 0.002
PERFORMANCE GROWTH
 Asset Growth Rate 1.045 %
 Revenue Growth 7.226 %
Revenue Growth QoQ 260.399 %
Revenue Growth YoY -16.54 %
Revenue Growth IPRWA high: 54.001 %
median: 12.969 %
mean: 10.187 %
MLAB: 7.226 %
low: -28.254 %
 Earnings Growth 291.111 %
Earnings Growth QoQ 2279.524 %
Earnings Growth YoY -319.706 %
Earnings Growth IPRWA MLAB: 291.111 %
high: 100.0 %
mean: 10.242 %
median: 6.667 %
low: -142.105 %
MARGINS
 Gross Margin 64.176 %
Gross Margin QoQ 4.414 %
Gross Margin YoY 1.445 %
Gross Margin IPRWA high: 96.557 %
median: 64.538 %
MLAB: 64.176 %
mean: 62.783 %
low: -16.207 %
 EBIT Margin 11.719 %
EBIT Margin QoQ 46.433 %
EBIT Margin YoY 1077.789 %
EBIT Margin IPRWA high: 33.51 %
median: 20.883 %
mean: 20.746 %
MLAB: 11.719 %
low: -144.871 %
 Return On Sales (ROS) 12.245 %
Return On Sales QoQ 57.431 %
Return On Sales YoY 1130.653 %
Return On Sales IPRWA high: 35.479 %
mean: 22.001 %
median: 21.965 %
MLAB: 12.245 %
low: -169.778 %
CASH FLOW
 Free Cash Flow (FCF) 18.0 M
 Free Cash Flow Yield 4.073 %
Free Cash Flow Yield QoQ 132.477 %
Free Cash Flow Yield YoY 64.102 %
Free Cash Flow Yield IPRWA MLAB: 4.073 %
high: 3.107 %
median: 0.969 %
mean: 0.898 %
low: -15.714 %
 Free Cash Growth 152.763 %
Free Cash Growth QoQ -78.379 %
Free Cash Growth YoY -62.379 %
Free Cash Growth IPRWA high: 265.331 %
MLAB: 152.763 %
mean: 4.868 %
median: -0.761 %
low: -303.638 %
 Free Cash To Net Income 4.965
 Cash Flow Margin 16.195 %
 Cash Flow To Earnings 2.906
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 0.839 %
Return On Assets QoQ 46.678 %
Return On Assets YoY -323.138 %
Return On Assets IPRWA high: 15.87 %
mean: 2.025 %
median: 1.556 %
MLAB: 0.839 %
low: -29.663 %
 Return On Capital Employed (ROCE) 2.006 %
 Return On Equity (ROE) 0.019
Return On Equity QoQ 40.159 %
Return On Equity YoY -280.0 %
Return On Equity IPRWA high: 0.174
mean: 0.03
median: 0.028
MLAB: 0.019
low: -0.518
 DuPont ROE 1.988 %
 Return On Invested Capital (ROIC) 1.708 %
Return On Invested Capital QoQ 57.13 %
Return On Invested Capital YoY 153.037 %
Return On Invested Capital IPRWA high: 6.199 %
mean: 2.689 %
median: 2.127 %
MLAB: 1.708 %
low: -19.559 %

Six-Week Outlook

The technical picture favors a bullish short-term bias: directional indicators, a MACD crossover, and dip‑and‑reversal behavior across RSI and the 12‑day EMA point toward continued upward pressure. MRO’s negative but rising reading implies room to re-rate toward WMDST’s target. Key near-term risks include the leadership transition and elevated leverage; these items could create episodic volatility even while technical momentum supports upside. For swing-focused timeframes, monitor momentum confirmation and news flow around the CEO transition and insider activity for event-driven moves rather than relying solely on momentum signals.

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. (NASDAQ:MLAB) develops and manufactures a diverse range of life sciences tools and quality control products. Serving markets across North America, Europe, the Asia Pacific, and globally, Mesa Laboratories addresses critical needs in various industries. The Sterilization and Disinfection Control segment provides biological, chemical, and cleaning indicators, essential for evaluating sterilization and decontamination processes in the pharmaceutical, medical device, and healthcare sectors. This segment also extends testing and laboratory services to dental and pharmaceutical industries. In the Clinical Genomics segment, Mesa Laboratories offers the MassARRAY system, a genetic analysis tool, along with consumables like chips, panels, and chemical reagents. These tools support clinical labs in DNA sample analysis for genetic disease testing, pharmacogenetics, oncology, and more. The Biopharmaceutical Development segment delivers automated systems for protein analysis and peptide synthesis, including Gyrolab and PurePep product lines. The Calibration Solutions segment provides quality control products for measuring critical parameters in environmental and process monitoring, as well as medical device and pharmaceutical manufacturing. Products include continuous monitoring systems, dialysate meters, data loggers, and gas flow calibration equipment, marketed under brands such as DialyGuard, ViewPoint, and DataTrace. Established in 1982, Mesa Laboratories is headquartered in Lakewood, Colorado.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.